SVRA — Savara Inc.

Savara (SVRA) Q2 2020 Earnings Call Summary

1. Key Financial Results and Metrics

• Net Loss: $9.4 million for Q2 2020, or $0.16 per share, a significant decrease from a net loss of $21.9 million, or $0.57 per share, in Q2 2019.
• Research and Development Expenses: Decreased by 42% to $6.1 million, down from $10.5 million in the prior year, attributed to lower study costs and wrapping up enrollment for ongoing studies.
• General and Administrative Expenses: Decreased by 26% to $3.1 million from $4.2 million, primarily due to reduced commercial activities.
• Cash Position: Approximately $100 million in cash, cash equivalents, and short-term investments as of June 30, 2020, with $25 million in debt. The company expects sufficient capital to fund operations through upcoming initiatives.

2. Strategic Updates and Business Highlights

• IMPALA 2 Study: The design for the Phase III IMPALA 2 clinical study has been finalized, aiming to start in Q1 2021 with a sample size of 160 patients. The study will focus on the efficacy of Molgradex for aPAP (Alveolar Proteinosis) with a primary endpoint of lung function measured by DLCO.
• COVID-19 Mitigation: Proactive measures are being implemented to minimize disruptions due to COVID-19, including telemedicine visits and ensuring drug supply continuity.
• AVAIL and ENCORE Studies: Enrollment for the AVAIL study was lower than expected (133 out of 150 target), while the ENCORE study is 50% enrolled. Both studies faced challenges due to COVID-19 but continued with the majority of enrolled patients.

3. Forward Guidance and Outlook

• Top-Line Results: Anticipated for the AVAIL study in early 2021. The company is optimistic about the potential role of AeroVanc in treating CF infections despite competitive pressures from newly approved treatments like Trikafta.
• Future Financing: Options for financing the Phase III programs include potential partnerships and project financing.
• Transition to Webcasts: The company plans to move away from quarterly earnings calls to webcasts aligned with significant news flow.

4. Bad News, Challenges, or Points of Concern

• Enrollment Challenges: Lower-than-expected enrollment in the AVAIL study raises concerns about the robustness of data and potential impacts on market addressability.
• Impact of Competitive Treatments: The introduction of Trikafta may affect the market for AeroVanc, as it does not assess combinations with this new treatment.
• COVID-19 Risks: Ongoing uncertainties related to the pandemic could impact study timelines and patient enrollment.

5. Notable Q&A Insights

• Study Site Distribution: The IMPALA 2 study will include approximately 20 sites in the U.S. and Canada, with additional sites across the EU, Japan, and Korea.
• FDA Discussions: The company aims to have discussions with the FDA regarding aPAP as soon as feasible, likely in late 2020 or early 2021, and plans to run studies in parallel once the design is finalized.
• Concerns on Whole Lung Lavage: There were inquiries about the impact of whole lung lavage on DLCO measurements, with the company acknowledging previous limitations but expressing optimism for improved outcomes in the upcoming study.

Overall, Savara is navigating a challenging landscape but remains focused on advancing its clinical programs while managing costs effectively. The company is optimistic about its strategic initiatives, particularly the IMPALA 2 study, despite facing competitive and operational challenges.